Study of the Efficacy, Safety, and Tolerability of Serlopitant for the Treatment of Chronic Pruritus of Unknown Origin

NCT03841331 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

233

Enrollment

INDUSTRY

Sponsor class

Conditions

Pruritus

Interventions

DRUG: 5 mg Serlopitant Tablets
DRUG: Matching Placebo Tablets

Sponsor

Vyne Therapeutics Inc.